Repligen Co. (NASDAQ:RGEN) Shares Sold by Pitcairn Co.

Pitcairn Co. trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,454 shares of the biotechnology company’s stock after selling 130 shares during the quarter. Pitcairn Co.’s holdings in Repligen were worth $641,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Signaturefd LLC increased its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new stake in shares of Repligen during the fourth quarter worth approximately $29,000. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the third quarter worth $37,000. Quarry LP raised its holdings in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RGEN shares. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $178.64.

Repligen Stock Down 8.0 %

Repligen stock opened at $111.94 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a one year low of $106.78 and a one year high of $182.52. The company has a 50-day simple moving average of $150.03 and a 200-day simple moving average of $147.51. The firm has a market capitalization of $6.29 billion, a P/E ratio of -219.49, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.